Advances in Clinical Medicine
Vol. 11  No. 07 ( 2021 ), Article ID: 43780 , 4 pages
10.12677/ACM.2021.117434

原发性子宫弥漫性大B细胞淋巴瘤1例并文献 复习

隋磊,纪晓宇,姚勤

青岛大学附属医院妇科,山东 青岛

收稿日期:2021年6月7日;录用日期:2021年6月28日;发布日期:2021年7月9日

摘要

目的:探讨原发性子宫弥漫性大B细胞淋巴瘤的临床表现及诊治要点。方法:对1例原发性子宫弥漫性大B细胞淋巴瘤的患者进行回顾性分析并文献复习。结果:本例患者为69岁女性,以绝经后阴道流血为初期症状,入院行择期手术治疗,最终被诊断为原发性子宫弥漫性大B细胞淋巴瘤。结论:原发性子宫淋巴瘤是一种极为罕见的疾病,临床表现无特异性。治疗方面现以根治性手术联合化疗为主。

关键词

子宫,淋巴瘤,原发性,结外淋巴瘤,治疗

Primary Uterine Diffuse Large B-Cell Lymphoma: A Case Report and Literature Review

Lei Sui, Xiaoyu Ji, Qin Yao

Gynaecology Department, Qingdao University Affiliated Hospital, Qingdao Shandong

Received: Jun. 7th, 2021; accepted: Jun. 28th, 2021; published: Jul. 9th, 2021

ABSTRACT

Objective: To investigate the clinical manifestations, diagnosis and treatment of primary uterine diffuse large B-cell lymphoma. Methods: A case of primary uterine diffuse large B-cell lymphoma was analyzed retrospectively and the literature was reviewed. Results: The patient was a 69-year-old woman with postmenopausal vaginal bleeding as the initial symptom, who was admitted to hospital for elective surgery, and was finally diagnosed as primary uterine diffuse large B-cell lymphoma. Conclusion: Primary uterine lymphoma is a rare disease with no specific clinical manifestations. Radical surgery combined with chemotherapy is the main treatment.

Keywords:Uterus, Lymphoma, Primary, Extranodal Lymphoma, Treatment

Copyright © 2021 by author(s) and Hans Publishers Inc.

This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

http://creativecommons.org/licenses/by/4.0/

1. 引言

原发于女性生殖系统的非霍奇金淋巴瘤极为罕见,它约占所有结外淋巴瘤的0.2%~1.1% [1]。由于此类疾病特殊的原发部位和极低的发生率,大部分患者通常先在妇科进行诊治。弥漫性大B细胞淋巴瘤是原发于女性生殖系统的非霍奇金淋巴瘤中最常见的一种类型 [2]。本文报道1例以“绝经后阴道流血”为初期症状累及宫颈和宫体的原发性子宫弥漫性大B细胞淋巴瘤,并对国内外相关文献进行回顾,以提高对此类罕见疾病的认知。本文患者已知情并同意报道。

2. 临床资料

患者,女,69岁。因“绝经后阴道流血1月余”于当地医院就诊,行宫颈筛查示阴性,进一步行诊断性刮宫,病理提示:子宫内膜坏死组织。后于青岛大学附属医院门诊就诊,行经阴道超声示:(1) 子宫宫颈至子宫肌层回声减低,肿瘤性?(子宫肌壁回声欠均匀,宫颈至子宫肌层回声减低,范围约8.1 × 6.1 × 6.3 cm,CDFI:内见多发条状血流信号);(2) 宫腔积液(宫腔分离扩张,较宽处约0.7 cm,透声可,单层内膜厚约0.3 cm,内回声欠均匀)。行肿瘤组织脱氧核糖核酸(DNA)测序示:淋巴细胞增殖性疾病。

患者于2021年4月26日因“子宫肿瘤性质待诊,高血压1级(高危) 2型糖尿病”入院。既往身体一般,患有“高血压病”30余年,患有“2型糖尿病”20余年,口服药物治疗,血压及血糖控制情况可。有“青霉素”过敏史,无手术史。G2P2L2A0,初潮18岁,月经规律,于22年前自然绝经。妇科查体:外阴发育正常,阴道通畅,宫颈肥大,下唇毛细血管明显,子宫前位,如孕3月大小,活动可,无压痛,双侧附件区未见明显异常。患者入院后行血常规 + CRP:单核细胞比率11.60%,嗜酸性粒细胞比率0.20%,单核细胞计数0.65 × 109/L,嗜酸性粒细胞计数0.01 × 109/L;女性肿瘤标志物:NSE 23.09 ng/mL;肝肾功能正常;体表肿物超声检查:左锁骨上偏内侧见2个肿大淋巴结,大者0.9 × 0.5 cm,髓质尚清,考虑反应增生性可能;盆腔动态CT增强:子宫体积明显增大,见团块影,最大截面约70 mm × 64 mm,增强扫描不均匀轻中度强化,宫腔扩张,宫底左侧部见明显强化结节影突入宫腔,长径约13 mm。双侧髂血管走形区未见明显肿大淋巴结影。右耻骨见结节状高密度影,骨岛?膀胱充盈可,膀胱壁未见明显增厚,其内未见明显异常密度影。直肠壁未见明显增厚。患者完善入院检验检查后,于2021年4月30日行腹腔镜下全子宫切除 + 双侧输卵管卵巢切除术。术中见:子宫增大如3个月妊娠大小,下段呈桶状膨隆,周围见多发新生血管,双侧输卵管–卵巢外观未见明显异常,与周围组织无粘连,盆腔无腹水。大体标本:子宫标本带双侧附件及少量阴道壁,子宫大小15.5 * 10 * 4.5 cm,宫颈外口直径3 cm,宫颈管长3.3 cm,宫腔深10.5 cm,内膜大部分粗糙,肌壁厚3.5 cm,内膜下方及宫颈管粘膜下方肌层内可见灰白区,范围7 * 6 cm,质脆,侵犯肌壁全层,宫颈内口处破碎,结构辨认不清,宫颈管内可见肿物累及,布满整个宫颈管,阴道壁范围5 * 0.6 cm。双侧卵巢及输卵管未见明显异常。术后病理结果:子宫非霍奇金淋巴瘤,肿瘤细胞中等大小,胞浆透亮,弥漫浸润性生长伴坏死,神经侵犯(+),血管壁侵犯(+),间质可见纤维间隔,结合形态学及免疫组化,符合高侵袭性B细胞淋巴瘤,意见为弥漫性大B细胞淋巴瘤(NOS,Non-GCB型)。肿瘤侵犯宫壁全层及宫颈管,阴道断端未见肿瘤累及,双侧宫旁未见肿瘤累及。免疫组化示肿瘤细胞:CD3 (−),CD20 (+),CD5 (−),CD10 (−),CD23 (−),CD30 (−),Bcl-2 (−),Bcl-6 (散在弱+),CD43 (−),CD25 (−),CyclinD1 (−),c-myc (−),MUM1 (+),p53 (弱+,约50%),CD138 (−),ALK(SP8) (−),Pax-5 (+),Ki-67 (+) 90%,HHV8 (−)。EBER (原位杂交) (−)。

术后患者于淋巴瘤科就诊,完善相关检验检查,超声示:右侧腋下淋巴结肿大,性质待诊,提示:右乳外上腺体边缘见2.6 * 1.9 cm低回声肿块,形态欠规则,边界欠清,质地硬,CDFI:周边见条状血流信号。患者行骨髓穿刺活检术,细胞学、流式及活检均未见明显异常。患者排除化疗禁忌后,于2021-05-29行第1周期R-CHOP方案(利妥昔单抗 + 环磷酰胺 + 长春新碱 + 吡柔比星 + 醋酸泼尼松)化疗,过程顺利。现患者一般情况尚可,仍在接受治疗中。

3. 讨论

非霍奇金淋巴瘤是一种淋巴造血系统的恶性肿瘤,它可以发生在淋巴结或者其他的淋巴组织 [3]。其中,原发于女性生殖系统的非霍奇金淋巴瘤是极为罕见的,并且它的发病机制尚不明确 [1]。根据统计,原发于女性生殖系统的非霍奇金淋巴瘤最常见于卵巢(37.0%),其次是宫颈(21.4%)、子宫(16.5%)、阴道(11.8%)等处 [4]。它的组织学类型以弥漫性大B细胞淋巴瘤为主(59.8%)。

原发性子宫淋巴瘤的患者由于原发部位的特殊性,常因妇科症状于妇科就诊后行手术治疗,其初期症状主要包括异常子宫出血、腹胀和腹痛 [5]。因此,患者一般在以妇科恶性肿瘤为前提的根治性手术后确诊。近年来,有学者提出磁共振成像(MRI, magnetic resonance imaging)有助于在术前辨别原发性子宫淋巴瘤 [6] [7]。根据研究,原发性子宫恶性淋巴瘤在MRI评估中表现为T2WI呈现高信号的非外向性生长的肿瘤,并且肿瘤组织一般不侵袭子宫内膜和宫颈粘膜。

Fox等人提出了原发性子宫淋巴瘤的诊断标准:(1) 初诊时病灶局限于子宫;(2) 全身检查中未发现身体其他部位有肿瘤的存在;(3) 外周血检查排除白血病的可能性;(4) 如果术后手术部位出现了继发性的淋巴瘤组织,时间间隔须在两个月以上 [8]。本例患者主要表现为绝经后阴道流血,既往无血液疾病病史,行超声示:宫颈至子宫肌层回声减低,行肿瘤组织脱氧核糖核酸(DNA)测序提示:淋巴细胞增殖性疾病,术前影像学评估未发现其余异常病灶。术后组织病理报告示:弥漫性大B细胞淋巴瘤,肿瘤侵犯宫壁全层及宫颈管。据此,患者确诊为原发性子宫弥漫性大B细胞淋巴瘤。

目前对于原发性子宫淋巴瘤的治疗,大多数学者推荐以手术联合化疗为主的方式。其中,化疗通常会选择针对侵袭性非霍奇金淋巴瘤的CHOP或者R-CHOP方案 [4]。有研究显示,在原发性子宫颈弥漫性大B细胞淋巴瘤中,单纯应用R-CHOP方案化疗的患者预后良好,部分患者可以获得完全缓解 [9] [10]。然而,目前还没有针对原发性子宫淋巴瘤的治疗指南,大部分患者在术后病理结果明确后才可以进行针对非霍奇金淋巴瘤的治疗。

综上所述,原发性子宫淋巴瘤是一种极为罕见的疾病,其临床表现无特异性。在子宫肿瘤的鉴别诊断中,MRI可能有助于诊断,确诊原发性子宫淋巴瘤需要依靠组织病理学检查。治疗方面以根治性手术联合化疗为主。目前仍需要更多关于原发于女性生殖系统淋巴瘤的病例和数据进行研究,以制定最佳治疗方案并改善患者的预后。

文章引用

隋 磊,纪晓宇,姚 勤. 原发性子宫弥漫性大B细胞淋巴瘤1例并文献复习
Primary Uterine Diffuse Large B-Cell Lymphoma: A Case Report and Literature Review[J]. 临床医学进展, 2021, 11(07): 2992-2995. https://doi.org/10.12677/ACM.2021.117434

参考文献

  1. 1. Lagoo, A.S. and Robboy, S.J. (2006) Lymphoma of the Female Genital Tract: Current Status. International Journal of Gynecological Pathology, 25, 1-21. https://doi.org/10.1097/01.pgp.0000183049.30212.f9

  2. 2. Cao, X.X., Li, J., Cai, H., Zhang, W., Duan, M.H. and Zhou, D.B. (2017) Patients with Primary Breast and Primary Female Genital Tract Diffuse Large B Cell Lymphoma Have a High Frequency of MYD88 and CD79B Mutations. Annals of Hematology, 96, 1867-1871. https://doi.org/10.1007/s00277-017-3094-7

  3. 3. Paes, F.M., Kalkanis, D.G., Sideras, P.A. and Serafini, A.N. (2010) FDG PET/CT of Extranodal Involvement in Non-Hodgkin Lymphoma and Hodgkin Disease. RadioGraphics, 30, 269-291. https://doi.org/10.1148/rg.301095088

  4. 4. Nasioudis, D., Kampaktsis, P.N., Frey, M., Witkin, S.S. and Holcomb, K. (2017) Primary Lymphoma of the Female Genital Tract: An Analysis of 697 Cases. Gynecologic Oncology, 145, 305-309. https://doi.org/10.1016/j.ygyno.2017.02.043

  5. 5. Ishii, Y., Fujisawa, S., Ando, T., Suzuki, T., Ishiyama, Y., Kishimoto, K., Hattori, Y., Nakajima, Y., Miyazaki, T., Takasaki, H., Matsumoto, K., Koharazawa, H., Taguchi, J., Fujimaki, K., Sakai, R. and Nakajima, H. (2018) Primary Uterine Lymphoma: The Yokohama Cooperative Study Group for Hematology (YACHT) Study. Asia Pacific Journal of Clinical Oncology, 14, e455-e459. https://doi.org/10.1111/ajco.13049

  6. 6. Saleh, G.A., Alghandour, R., Rashad, E.Y., Tawfik, A.M. and Elmokadem, A.H. (2021) The Adjunctive Value of Diffusion Weighted Imaging in Diagnosis and Follow up of Uterovaginal Diffuse B-Cell Lymphoma: A Case Report and Literature Review. Current Medical Imaging. https://doi.org/10.2174/1573405617666210120094711

  7. 7. Sugimoto, M., Koyama, K., Ichimura, T., Shimono, T., Hashiguchi, Y. and Miki, Y. (2019) Comparison of MR Imaging Features of Uterine Neuroendocrine Carcinoma and Uterine Malignant Lymphoma. Abdominal Radiology, 44, 3377-3387. https://doi.org/10.1007/s00261-019-02201-1

  8. 8. Fox, H. and More, J.R. (1965) Primary Malignant Lymphoma of the Uterus. Journal of Clinical Pathology, 18, 723-728. https://doi.org/10.1136/jcp.18.6.723

  9. 9. Cubo, A.M., Soto, Z.M., Cruz, M., Doyague, M.J., Sancho, V., Fraino, A., Blanco, Ó., Puig, N., Alcoceba, M., González, M. and Sayagués, J.M. (2017) Primary Diffuse Large B Cell Lymphoma of the Uterine Cervix Successfully Treated by Combined Chemotherapy Alone: A Case Report. Medicine (Baltimore), 96, e6846. https://doi.org/10.1097/md.0000000000006846

  10. 10. Goda, J.S., Gaikwad, U., Narayan, A., Kurkure, D., Yadav, S., Khanna, N., Jain, H., Bagal, B., Epari, S., Singh, P., Sengar, M. and Laskar, S. (2020) Primary Diffuse Large B Cell Lymphoma of Uterine Cervix: Treatment Outcomes of a Rare Entity with Literature Review. Cancer Reports (Hoboken), 3, e1264. https://doi.org/10.1002/cnr2.1264

期刊菜单